The current state of randomized clinical trial evidence for prostate brachytherapy.
Brachytherapy
Combination therapy
HDR
LDR
Prostate cancer
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
30
10
2018
revised:
26
03
2019
accepted:
09
04
2019
pubmed:
8
5
2019
medline:
12
9
2020
entrez:
8
5
2019
Statut:
ppublish
Résumé
Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy. Evidence from completed randomized controlled trials is the focus of this review with a presentation also of important ongoing trials. Gaps in knowledge are identified where future investigation may be fruitful with intent to inspire well-designed prospective studies with standardized treatment that focuses on improving oncological outcomes, reducing morbidity, or maintaining quality of life.
Identifiants
pubmed: 31060795
pii: S1078-1439(19)30142-5
doi: 10.1016/j.urolonc.2019.04.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-610Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.